Across all targets studied here, the expression in AR + /NE+ tumors mostly resembled AR + /NE- tumors, highlighting that this subtype exhibits predominantly luminal prostatic adenocarcinoma molecular features and not those of NEPC. This evidence concerns the gene AR and prostate adenocarcinoma.